Media headlines about Galapagos NV (NASDAQ:GLPG) have trended positive recently, Accern reports. The research firm identifies negative and positive media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Galapagos NV earned a media sentiment score of 0.26 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 45.6928129217892 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Here are some of the media stories that may have impacted Accern Sentiment’s rankings:

Shares of Galapagos NV (NASDAQ:GLPG) traded up $0.28 during mid-day trading on Friday, reaching $92.23. 35,122 shares of the company’s stock traded hands, compared to its average volume of 152,242. Galapagos NV has a 52 week low of $57.86 and a 52 week high of $104.12.

GLPG has been the subject of several recent research reports. Nomura raised their price target on shares of Galapagos NV from $108.00 to $124.00 and gave the company a “buy” rating in a research report on Friday, August 11th. BidaskClub raised shares of Galapagos NV from a “sell” rating to a “hold” rating in a research report on Thursday, August 17th. Stifel Nicolaus reissued a “buy” rating and issued a $120.00 price target on shares of Galapagos NV in a research report on Sunday, October 29th. Morgan Stanley reissued an “overweight” rating and issued a $123.00 price target (up previously from $92.00) on shares of Galapagos NV in a research report on Friday, October 6th. Finally, Royal Bank Of Canada initiated coverage on shares of Galapagos NV in a research report on Thursday, September 14th. They issued a “sector perform” rating and a $98.00 price target for the company. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $111.00.

ILLEGAL ACTIVITY WARNING: “Galapagos NV (GLPG) Earning Favorable Media Coverage, Study Finds” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another site, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this story can be read at

Galapagos NV Company Profile

Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.

Insider Buying and Selling by Quarter for Galapagos NV (NASDAQ:GLPG)

Receive News & Stock Ratings for Galapagos NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos NV and related stocks with our FREE daily email newsletter.